Shanghai Allist Pharmaceuticals
Shanghai Allist Pharmaceuticals Co Ltd is a Chinese biopharmaceutical enterprise focused on discovering, developing, and commercializing targeted oncology therapeutics for lung cancer. The company commercializes furmonertinib (Iressa-class third-generation EGFR inhibitor) for the treatment of non-small cell lung cancer (NSCLC) with EGFR mutations. Principal revenue is generated from direct product sales of furmonertinib prescription tablets directly to medical distributors, hospital networks, and retail pharmacies across China. Core end markets encompass thoracic oncology clinics, clinical hospital networks, and lung cancer prescription patients in Mainland China. Shanghai Allist Pharmaceuticals holds a market-leading position in China's domestic targeted lung cancer therapy sector. The company is headquartered in Shanghai, China, and its common shares trade on the STAR Market of the Shanghai Stock Exchange.
4 of the funds FundTelligence covers report a position in Shanghai Allist Pharmaceuticals.
- Legal name
- Shanghai Allist Pharmaceuticals Co Ltd
- Sector
- Health Care
- Country
- China
- Funds holding it
- 4
Funds holding Shanghai Allist Pharmaceuticals
- KLP AksjeFremvoksende Markeder Flerfaktor — KLP · 0.22 % (full portfolio disclosed, June 2026)
- KLP AksjeFremvoksende Markeder Indeks — KLP · 0.01 % (full portfolio disclosed, June 2026)
- BlackRock iShares MSCI EM IMI Screened UCITS ETF — BlackRock · 0.0 % (full portfolio disclosed, October 2026)
- Handelsbanken Emerging Markets Index — Handelsbanken · 0.0 % (full portfolio disclosed, September 2026)